This site is intended for healthcare professionals only

COVID-19: Oxford-Astrazeneca vaccine reduces spread

Written by: | Published:

The efficacy of the vaccine was teste in the study The efficacy of the vaccine was tested in the study

The Oxford-Astrazeneca vaccine significantly reduces the chances of spread after only one jab, a new study suggests.

The study, published in Preprints with The Lancet, also found that the vaccine provides roughly 75% protection against COVID. After the second dose vaccine efficacy from two standard doses is 82.4% with the 3-month interval being used in the UK. Additionally, the study suggests that a single dose can eliminate severe illness among those who contract Coronavirus.

Read more: Over 4 million people receive first dose of COVID-19 vaccine

‘These new data provide an important verification of the interim data that was used by more than 25 regulators including the MHRA and EMA to grant the vaccine emergency use authorisation,’ said Professor Andrew Pollard, Chief Investigator of the Oxford Vaccine Trial.

‘It also supports the policy recommendation made by the Joint Committee on Vaccination and Immunisation (JCVI) for a 12-week prime-boost interval, as they look for the optimal approach to roll out, and reassures us that people are protected from 22 days after a single dose of the vaccine.’

Read more: COVID-19: New Oxford vaccine rolled out to general practice services

The study also suggests that suggest that it is the dosing interval and not the dosing level which has a great impact on the efficacy of the vaccine. This is in line with previous research supporting greater efficacy with longer prime-boost intervals done with other vaccines such as influenza, Ebola and malaria.

‘This is a really encouraging study – THANK YOU to the teams at University of Oxford and AstraZeneca,’ tweeted Matt Hancock, the Health and Social Care Secretary.

‘Vaccines are the way out of this pandemic & we are making fantastic progress vaccinating the most vulnerable.’

Learn more about addressing influenza vaccine effectiveness: cell-based influenza vaccine technology as an option

Learn more about addressing the burden of influenza in older adults in the UK

Register here to receive updates when new webinars are released

What do you think? Leave a comment below or tweet your views to @IndyNurseMag

This material is protected by MA Healthcare Ltd copyright.
See Terms and Conditions.



Please view our Terms and Conditions before leaving a comment.

Change the CAPTCHA codeSpeak the CAPTCHA code

Read a free issue from Practice Nursing

Register to read a free issue from our sister publication, Practice Nursing.

Including articles on asthma, diabetes and more. Read your copy.


Sign up to the newsletter


Independent Nurse is the professional resource for primary care and community nurses, providing clinical articles for practice nurses and prescribers.


Subscribe to our newsletter and stay up to date with the latest nursing news.

Stay Connected

Stay social with Independent Nurse by following us on Twitter, liking us on Facebook or connecting on LinkedIn.


Need access to some of our older articles? You can view our archive, or alternatively contact us.

Contact Us

MA Healthcare Ltd.
St Jude's Church, Dulwich Road
London, SE24 0PB

Tel: +44 (0)20 7738 5454
Registered in England and Wales No. 01878373

Meet the team


Find out how to contribute to Independent Nurse here.